DCM
ECYT

Dupont Capital Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Dupont Capital Management’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-72,204
Closed -$375K – 653
2015
Q2 		$375K Hold
72,204
– – 0.01% 537
2015
Q1 		$452K Hold
72,204
– – 0.01% 517
2014
Q4 		$454K Sell
72,204
-37,910
-34% -$231K 0.01% 553
2014
Q3 		$669K Buy
110,114
+52,264
+90% +$357K 0.01% 521
2014
Q2 		$381K Buy
+57,850
New +$652K 0.01% 598

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dupont Capital Management's ECYT Position: Q3 2015 in Review

Dupont Capital Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q3 2015, closing a stake of 72,204 shares — an estimated $375K sold.

Dupont Capital Management first reported a position in ECYT in Q2 2014 and held it in 5 quarters. The position peaked at $669K in Q3 2014. 104 funds tracked by Wall St. Rank hold ECYT as of Q3 2015.

  • Dupont Capital Management reported no remaining Endocyte, Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
  • Dupont Capital Management sold 72,204 Endocyte, Inc. Common Stock shares in Q3 2015, an estimated $375K.
  • Dupont Capital Management first reported a position in Endocyte, Inc. Common Stock in Q2 2014 and held it in 5 quarters.
  • Dupont Capital Management's Endocyte, Inc. Common Stock position peaked at $669K in Q3 2014.
  • 104 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q3 2015.

Based on Dupont Capital Management's 13F filing for Q3 2015, filed 23 Oct 2015.